ANGLE: Funding, Investors & Team (Sep 2026)

Point is a financially determined expert clinical symptomatic organization with spearheading items in malignant growth diagnostics and fetal wellbeing. It likewise possesses a fruitful expert innovation consultancy and a significant interest in a business with a one of a kind PC illustrations innovation stage. The business has developed so it currently centers around its laid out 90%+ possessed organizations with one of a kind high-esteem patent-safeguarded clinical innovations tending to extravagant business sectors. Point's lead item is the Parsortix cell partition gadget, which can catch extremely uncommon coursing growth cells (CTCs) in disease patient blood - in any event, when there is short of what one CTC in one billion solid cells. Point has sent off an item for the exploration market and is expecting to get CE Mark administrative endorsement for the clinical market in 2013 with FDA endorsement in 2014. Point has an exceptionally proficient venture model. Costs are limited by the utilization of outsider joint efforts and organizations and by the commitment of its counseling business to overheads. The current organizations are more than six years of age. Point's endeavors are coordinated to amplifying investor gets back from these organizations and there are no designs to set up new organizations. Risk is additionally counterbalanced by the income creating PC illustrations organization, which can possibly convey a close term capital re-visitation of ANGLE. Point was established by Andrew Newland in 1994 to overcome an issue among research and the market. Point's plan of action is to set up, own and work innovation organizations to market a-list research.

ANGLE has raised $35.7M across 2 rounds on record. The most recent is an undisclosed round of $11.9M announced in Jun 2024.

ANGLE's most recent funding round on record is an undisclosed round of $11.9M, announced in Jun 2024.

FundedIQ lists Andrew Newland (Founder) at ANGLE.

ANGLE is based in Guildford, Surrey, United Kingdom.

ANGLE is in the 101-250 employee band.

ANGLE's latest round of $11.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.